New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:02 EDTQCOR, MNKMallinckrodt price target raised to $85 from $77 at Jefferies
Jefferies raised its price target for Mallinckrodt (MNK) shares to $85 after its survey indicated strong demand for Xartemis XR. The firm also sees significant upside in earnings power from the Questcor (QCOR) acquisition. Jefferies keeps a Buy rating on Mallinckrodt.
News For MNK;QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
16:57 EDTMNKHikma, Mallinckrodt among bidders for Roxane Labs, Bloomberg says
Hikma (HKMPY) and Mallinckrodt (MNK) are bidding for Boehringer's Roxane Labs business, reports Bloomberg, citing people with knowledge of the matter. Roxane Labs could end up being purchased for over $2.2B, Bloomberg adds. Reference Link
15:01 EDTMNKMallinckrodt, Perrigo among bidders for Roxane Labs, Bloomberg reports
Mallinckrodt (MNK), Perrigo (PRGO) and Hikma are among the potential bidders for Boehringer Ingelheim's Roxane Labs generic business, said Bloomberg, citing people with knowledge of the matter.
June 23, 2015
11:12 EDTMNKMallinckrodt management to meet with Guggenheim
Subscribe for More Information
June 18, 2015
06:57 EDTMNKMallinckrodt says Questcor facing multi-state antitrust probe
Subscribe for More Information
June 17, 2015
07:21 EDTMNKGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
June 16, 2015
10:29 EDTMNKGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use